首页> 美国卫生研究院文献>Internal Medicine >Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban
【2h】

Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban

机译:主动脉瘤相关的弥散性血管内凝血对华法林转用利伐沙班反应良好。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We describe a case in which uncontrolled chronic disseminated intravascular coagulation (DIC) caused by an aortic aneurysm that was exacerbated by chemotherapy for lung cancer, showed dramatic improvement when warfarin, which was being administered for atrial fibrillation, was replaced by rivaroxaban, a direct oral anticoagulant (DOAC). The present case is interesting because a DOAC was effective in treating DIC due to an aortic aneurysm, whereas warfarin, another oral anticoagulant, was ineffective. In controlling DIC, it is important to inhibit activated coagulation factors such as thrombin and activated factor X, rather than the coagulation factors, which act as substrates.
机译:我们描述了一种情况,其中由肺癌化疗引起的主动脉瘤加重的不受控制的慢性弥散性血管内凝血(DIC)在用华法林(用于房颤的药物)替代利伐沙班(直接口服)替代时显示出显着改善抗凝剂(DOAC)。本例很有趣,因为DOAC可有效治疗因主动脉瘤引起的DIC,而华法林(另一种口服抗凝药)无效。在控制DIC时,重要的是抑制活化的凝血因子(例如凝血酶和活化的因子X),而不是抑制充当底物的凝血因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号